Onlikon: Announcement on acceptance of ALK-N001 clinical trial applications for innovative drug injections
Onlikon: Announcement on the subsidiary finasteride API obtaining approval notice for the marketing application of chemical raw materials
Onlikon: Announcement on Obtaining a Drug Registration Certificate
Onlikon: Announcement on the Change of Continued Supervisory Sponsor Representative
Onlikon: Progress Announcement on the Repurchase of the Company\'s Shares
Onlikon: Announcement on Obtaining a Drug Registration Certificate
Onlikon: Announcement on Obtaining a Drug Registration Certificate
Onlikon: Progress Announcement on the Repurchase of the Company\'s Shares
Onlikon: Announcement on the cancellation of the pledge of some of the company\'s controlling shareholders\' shares
Onlikon: Announcement on the cancellation of the pledge of some of the company\'s controlling shareholders\' shares
Onlikon: 002940 Onlikon Investor Relations Management Information 20241223
Onlikon: Announcement on receiving government grants
Onlikon: 002940 Onlikon Investor Relations Management Information 20241213
Onlikon: Announcement on Subsidiaries Participating in Pharmaceutical Volume Procurement of Sanming Procurement Alliance to be selected
Onlikang: Announcement on the Company\'s Participation in the Tenth Batch of National Centralized Drug Procurement and Proposed Selection
Onlikang: Announcement on the company\'s cooperative products to be selected for the tenth batch of centralized procurement of national drugs
Onlikon: Announcement on Subsidiaries Obtaining Approval Numbers for Veterinary Drug Products
Onlikon: Announcement on the repurchase ratio of the company\'s shares reaching 1% and the progress of the repurchase
Onlikon: Notice on Obtaining a Notice of Approval for Supplementary Applications for Chemical Ingredients
Onlikon: Progress Announcement on the Repurchase of the Company\'s Shares